This Phase 2 clinical trial (NCT06530290) evaluates mirtazapine, a noradrenergic and specific serotonergic antidepressant, for the treatment of anxiety in Parkinson's disease (PD)[1]. Anxiety is one of the most common non-motor symptoms in PD, affecting up to 40% of patients, yet treatment options remain limited due to the sensitivity of PD patients to traditional anxiolytic medications.
Mirtazapine represents a promising therapeutic approach because it modulates both noradrenergic and serotonergic systems—pathways known to be affected in PD—and has a favorable side effect profile compared to traditional SSRIs and benzodiazepines.
| Attribute | Value |
|---|---|
| NCT ID | NCT06530290 |
| Phase | Phase 2 |
| Status | Recruiting |
| Intervention | Mirtazapine (15 mg once daily) |
| Condition | Parkinson's Disease, Anxiety |
| Participants | 64 (estimated) |
| Sponsor | Leila Dargahi, PharmD PhD |
| Location | Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| Start Date | June 2022 |
| Primary Completion | December 2025 |
| Completion | June 2026 |
Anxiety disorders in Parkinson's disease represent a significant non-motor complication:
Anxiety in PD differs from primary anxiety disorders in several ways:
The neurobiological basis of anxiety in PD involves multiple neurotransmitter systems:
Dopaminergic dysfunction:
Noradrenergic dysfunction:
Serotonergic dysfunction:
Current treatment options for anxiety in PD have significant limitations:
| Treatment | Limitations |
|---|---|
| SSRIs/SNRIs | Limited efficacy, potential worsen motor symptoms |
| Benzodiazepines | Risk of falls, sedation, cognitive impairment |
| Buspirone | Modest efficacy |
| CBT | Access barriers, variable response |
This highlights the need for novel therapeutic approaches like mirtazapine that can target multiple neurotransmitter systems simultaneously.
Mirtazapine is a tetracyclic antidepressant with a unique pharmacological profile:
Primary mechanisms:
Receptor binding profile:
| Receptor | Affinity | Effect |
|---|---|---|
| α2-adrenergic | High antagonist | ↑ Norepinephrine |
| 5-HT2A | High antagonist | ↑ Serotonergic |
| 5-HT2C | High antagonist | Anxiolytic, anorectic |
| 5-HT3 | Moderate antagonist | Reduces nausea |
| H1 | High antagonist | Sedation |
Mirtazapine has several properties that make it attractive for PD anxiety:
Prior studies have evaluated mirtazapine in Parkinson's disease:
Depression in PD:
Sleep in PD:
Inclusion criteria:
Exclusion criteria:
The trial uses a randomized, double-blind, placebo-controlled design:
| Arm | Intervention | Dose | Duration |
|---|---|---|---|
| Treatment | Mirtazapine | 15 mg daily | 12 weeks |
| Control | Placebo | N/A daily | 12 weeks |
Anxiety assessment:
HAM-A is the gold standard for anxiety measurement:
| Outcome | Instrument | Timepoints |
|---|---|---|
| Depression | Hamilton Depression Rating Scale (HAM-D) | Baseline, week 4, week 12 |
| Fatigue | Parkinson's Disease Fatigue Scale (PDFS) | Baseline, week 4, week 12 |
| Sleep | Parkinson's Disease Sleep Scale (PDSS) | Baseline, week 4, week 12 |
| Quality of Life | PDQL Questionnaire | Baseline, week 4, week 12 |
The rationale for mirtazapine in PD anxiety centers on its noradrenergic effects:
α2-adrenoceptor antagonism:
Mechanistic advantages:
The serotonergic effects of mirtazapine provide additional benefits:
PD patients frequently experience sleep fragmentation:
Parkinson's disease involves numerous non-motor symptoms that impact quality of life:
| Category | Symptoms |
|---|---|
| Neuropsychiatric | Depression, anxiety, apathy, psychosis |
| Sleep | Insomnia, RBD, restless legs, daytime sleepiness |
| Autonomic | Orthostatic hypotension, constipation, urinary dysfunction |
| Sensory | Hyposmia, pain, visual disturbances |
| Cognitive | Executive dysfunction, memory impairment, dementia[9] |
Treating anxiety in PD provides multiple benefits:
Mirtazapine's established safety profile supports its evaluation in PD:
Common adverse effects:
Less common but important:
Special considerations for the PD population:
Motor effects:
Cognitive effects:
Cardiovascular:
Key interactions to monitor in PD patients:
If successful, this trial could establish mirtazapine as a first-line treatment for PD anxiety:
Clinical practice impact:
Research directions:
Future studies may incorporate:
The NCT06530290 trial represents an important step in addressing anxiety in Parkinson's disease, one of the most common and debilitating non-motor symptoms. By evaluating mirtazapine—a noradrenergic and serotonergic modulator—this trial tests a mechanistically targeted approach that addresses the neurobiological basis of PD anxiety.
The scientific rationale is compelling: mirtazapine directly enhances noradrenergic neurotransmission, which is impaired due to locus coeruleus degeneration in PD, while also providing serotonergic modulation and sleep benefits. The established safety profile of mirtazapine in general populations supports its evaluation in the often-medically complex PD patient population.
Given the high prevalence of anxiety in PD and the limitations of current treatment options, successful results from this trial could significantly improve the standard of care for Parkinson's disease patients suffering from anxiety.
Evaluating the Effect of Mirtazapine on Anxiety in Parkinson's Disease Patients - ClinicalTrials.gov. 2024. ↩︎
Bruneau MA, et al. Anxiety and depression in Parkinson's disease. Journal of Neurology. 2011. ↩︎
Pontone GM, et al. Anxiety in Parkinson's disease. Movement Disorders. 2009. ↩︎
Ressler KJ, et al. Norepinephrine and anxiety. CNS Drugs. 2004. ↩︎
Menza M, et al. Depression and anxiety in Parkinson disease. Journal of Neuropsychiatry. 2010. ↩︎
Fritea L, et al. Mirtazapine in neurological disorders. Brain Sciences. 2023. ↩︎
Chen Y, et al. Mirtazapine for the treatment of Parkinson's disease depression. Parkinsonism and Related Disorders. 2017. ↩︎
Nutt DJ, et al. The neurobiology of anxiety disorders. Current Topics in Behavioral Neurosciences. 2008. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Barone P, et al. Parkinson's disease complications and non-motor symptoms. Lancet Neurology. 2009. ↩︎